Amrita Mitra

Amrita Mitra

Auto-generated profile, based on publicly available information

Amrita Mitra

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RPRanjan Preet
Ranjan Preet
AIAtiqul Islam
Atiqul Islam
JSJiyoung Shim
Jiyoung Shim
GRGaneshkumar Rajendran
Ganeshkumar Rajendran
AMAmrita Mitra
Amrita Mitra
JZJun Zhang
Jun Zhang
Lung cancer is the leading cause of cancer-related deaths worldwide. Although immunotherapy such as anti-programmed death-1 and its ligand 1 (PD-1/L1) is a standard treatment for advanced non-small cell lung cancer (NSCLC), many patients do not derive benefit directly. Several studies have elucidated new strategies to improve the antitumor immune response through gut microbiota modulation. However, it remains largely debatable regarding how gut microbiota remotely affect lung cancer microenvironment and subsequently modulate immunotherapy response. Here we show that commensal Bifidobacterium-derived extracellular vesicles (Bif.BEVs) can modulate the therapeutic effect of anti-PD-1 therapy in NSCLC. These Bif.BEVs are up-taken by lung cancer cells predominantly via dynamin-dependent endocytosis and upregulate PD-L1 expression through TLR4-NF-κB pathway. They also efficiently penetrate murine intestinal and patient-derived lung cancer organoids. Oral gavage of these Bif.BEVs result in their accumulation in tumors in mice. Using a syngeneic mouse model, Bif.BEVs are found to synergize the anti-tumor effect of anti-PD-1 via modulation of key cytokines, immune response and oncogenic pathways, and increase in tumor-infiltrating CD8+ T cells. Our study therefore identifies a link between Bif.BEVs and the tumor microenvironment, providing an alternative mechanism to explain how gut microbiota can influence immunotherapy response, particularly in tumors located anatomically distant from the gut.

2 July 2018 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
AMAmrita Mitra
Amrita Mitra
AMAmit Kumar Kumar Mandal
Amit Kumar Kumar Mandal

29 March 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
JSJared Sipes
Jared Sipes
SRSagar Rayamajhi
Sagar Rayamajhi
LBLeonidas E. Bantis
Leonidas E. Bantis
RMRashna Madan
Rashna Madan
AMAmrita Mitra
Amrita Mitra
AGAndrew Godwin
Andrew Godwin
The fallopian tube (FT) plays a crucial role in fertility, gynecological health, and high-grade serous ovarian cancer (HGSOC) development. Despite its importance, the spatial transcriptome of the FT’s distinct anatomical regions (fimbria, infundibulum, ampulla, and isthmus) remains underexplored. Using the GeoMx Digital Spatial Profiler (DSP) and a targeted ~1800 gene panel, we analyze premenopausal FT epithelium, identifying region-specific gene expression patterns. Our analysis reveals upregulation of mature ciliated cell markers (FOXJ1, MLF1, SPA17, and CTSS) approaching the fimbria, elevated ROS and apoptosis-related transcripts (TXNIP, PRDX5, BAD, GAS1) in the distal FT, and a switch in cell-cell adhesion transcripts (CDH1, CDH3) along the distal-to-proximal axis. We also provide evidence that MHC-II transcripts in the FT are differentially regulated throughout the menstrual cycle, with lower expression in follicular phase. These results suggest spatially regulated expression of FT transcripts with implications for fertilization and early neoplastic changes contributing to HGSOC.

9 January 2026 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
SRSagar Rayamajhi
Sagar Rayamajhi
JSJared Sipes
Jared Sipes
BNBidii Ngala
Bidii Ngala
AMAmrita Mitra
Amrita Mitra
MLMeizhang Li
Meizhang Li
AGAndrew Godwin
Andrew Godwin
Small extracellular vesicles (sEVs), lipid-bilayer delimited particles (50-200 nm) released by cells, are emerging as a promising class of liquid biopsy biomarkers for elusive cancers such as high-grade serous ovarian cancer (HGSOC). HGSOC originates from the fallopian tube (FT), progressing from p53 signatures to a precursor lesion known as serous tubal intraepithelial carcinoma (STIC). We hypothesize that sEVs contribute to ovarian cancer pathogenesis, carry cargo reflective of their site of origin, and serve as diagnostic biomarkers for early detection. To test this, we established a case-control cohort using archival plasma samples from 30 HGSOC patients (10 early-stage and 20 late-stage) and 40 healthy controls (HC). sEVs were enriched by size exclusion chromatography and profiled by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Across all samples, 1,078 EV-associated proteins (exo-proteins) were identified, including 52 upregulated in early-stage HGSOC vs HC, and 59 upregulated in late-stage HGSOC vs healthy controls (HC) (log2FC>1, p-value<0.05). Upregulated EV-proteins were prioritized based on FT origin and tissue expression in STIC lesions. Seven candidate biomarkers (MYL6, GSTP1, TTYH3, PRDX6, MUC1, MYH14, and PTGS1) were validated by immunohistochemistry in FT tissue harboring STIC lesions and in HGSOC tissues, as well as by western blotting in FT/HGSOC cell-derived EVs. These findings suggest that circulating exo-proteins upregulated in early-stage cancer disease reflect precursor lesions. A four-protein combinatorial panel (MUC1, MYL6, TTYH3, GSTP1), selected using Akaike Information Criterion (AIC), yielded an AUC of 0.975 and 90% sensitivity at 95% specificity for distinguishing early-stage HGSOC vs HC. Additionally, increased MUC1 levels in circulating sEVs were confirmed by immunoassay (AUC = 0.840 for early-stage HGSOC vs HC; AUC = 0.860 for late-stage HGSOC vs HC, p-value<0.05). In summary, our sEV proteomic analysis of early-stage HGSOC reveals exo-biomarkers associated with early FT lesions, offering a promising avenue for detecting disease while it remains confined to the fallopian tube.

25 April 2025 in JID Innovations
Verified
Journal Article
Open access
APAmy Petty
Amy Petty
ACAdela Rambi Cardones
Adela Rambi Cardones
YJYingai Jane Jin
Yingai Jane Jin
VJVaibhav Jain
Vaibhav Jain
EHEmily Hocke
Emily Hocke
JZJennifer Zhang
Jennifer Zhang
Cutaneous manifestations are the most common presenting sign of chronic graft-versus-host disease (GVHD), and the extent of cutaneous involvement is also highly correlated with prognosis. Very little is understood about the underlying pathogenesis underpinning injury at this location, especially the contribution of keratinocytes and other structural skin cells. We performed single-cell RNA sequencing to compare the transcriptome of epidermal and dermal chronic GVHD samples with that of healthy control samples. Our findings reveal unique nonimmunologic and immunologic changes in epidermal keratinocytes and dermal immune cells. Specifically, we observed upregulation of alarmins and inflammatory cytokines and downregulation of anti-reduction–oxidation and activator protein-1 pathway genes in the keratinocyte compartments. In dermal immune cell subsets, we showed increased CD8+ T, CD4+ T, CD4+Foxp3+ regulatory T, and NK cells in chronic GVHD, accompanied by increased signals of leukocyte functions, inflammatory responses, cytolysis, and macrophage M1 polarization. Finally, we also delineated the donor versus recipient cellular origin of nonimmune and immune cell populations in sex-mismatched chronic GVHD. Taken together, these data reveal complex keratinocyte and immune responses in cutaneous chronic GVHD, supporting future studies of skin cell contributions to pathogenesis and potential local treatment strategies.

21 July 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JSJared Sipes
Jared Sipes
DZDidi Zha
Didi Zha
SRSagar Rayamajhi
Sagar Rayamajhi
LBLeonidas E. Bantis
Leonidas E. Bantis
RMRashna Madan
Rashna Madan
AGAndrew Godwin
Andrew Godwin
Serous tubal intraepithelial carcinomas (STIC lesions) in the human fallopian tube epithelium (hFTE) are theorized to give rise to high grade serous ovarian cancers (HGSOC). Small extracellular vesicles (sEVs) are known to mediate key signaling in both normal and cancerous tissues, but few ex vivo systems exist for studying sEV impact on hFTE tissue. Here, we present a microfluidic tissue culture platform with combined spatial transcriptomic and proteomic readouts that allows us to profile dual responses in tissue exposed to sEV “messages”—capturing both short-term transcriptomic shifts in the tissue and long-term changes in protein cargo of secreted EVs (the “reply”). Using spatial transcriptomics, we show that the short-term 1-day exposure to ovarian cancer-derived sEVs alters expression of 68 transcripts in secretory cells, the progenitor of HGSOC, notably upregulating immune-related mRNA, including CXCL family chemokines, VCAM1, and pro-inflammatory mediators (NFKB1, IL1B, IFNA7/17). Additionally, we observed the long-term 14-day exposure to sEVs alters the expression of 7 transcripts and 25 EV cargo proteins of fallopian tube derived EVs (“secondary release EVs”) following stimulus from cancer EVs. Together, tissue transcriptomics and tissue-derived EV proteomics indicate that ovarian cancer derived sEVs rewire target cell signaling to modify the tubal immune landscape. This study provides insights into the early molecular changes associated with the pathogenesis of ovarian cancer in its tissue of origin, providing a platform to study EV-tissue interactions and identify how sEVs drive cell signaling reprogramming in hFTE.